Skip to content
May 11, 2024

Equity.Guru

Investment information for the new generation

Search

biotech stocks

Over the last 12 months, Revive Therapeutics (RVV.C) stock slipped 88% from $0.26 per share to a measly $0.03, but is Revive down for the count? Some analysts believe…
Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF), a leading specialty pharmaceutical company, has been making waves with record annual revenues, a new credit agreement, and the acquisition of the Canadian…
Specialty pharmaceuticals is a unique niche in the pharma sector. Where companies like Eli Lilly pour billions into developing a drug candidate from scratch with the very real possibility…
Specialty pharma company, Medexus Pharmaceuticals (MDP.TO) released fiscal Q3 2023 (quarter ended December 31st 2022) operating and financial results. The company has announced another record quarter with revenue of…
Medexus Pharmaceuticals (MDP.TO) today announced that it has reached an agreement with the provincial government of Quebec for government sponsored coverage of Cuvposa. The glycopyrrolate oral solution will be…
*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing…
Medexus Pharmaceuticals (MDP.TO) today announced preliminary estimates of the company’s revenue results for the quarter ended December 31st 2022 (fiscal Q3 2023). After Q2 2023 being Medexus’ strongest quarter…
Specialty pharma company Medexus Pharmaceuticals (MDP.TO) announced today that it plans to host a conference call at 8:00 am EST on Wednesday November 9th 2022. The call will discuss…
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company whose stock is on fire! The stock rallied 34% from its opening price to its highs last week. And it has…
Repare Therapeutics (RPTX) is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its…